Latest 5 articles from heartwire
- Air pollutants mediate effects on heart health through inflammation and thrombosis
May 17, 2012 17:15 EDT - Statins benefit those at much lower CV risk
May 16, 2012 18:30 EDT - Azithromycin may up chance of sudden cardiac death
May 16, 2012 17:00 EDT - So long, Plavix, what a ride! Clopidogrel patent expires
May 16, 2012 14:45 EDT - COMFORTABLE-AMI: Bioerodable polymer DES trumps bare metal in STEMI
May 16, 2012 10:50 EDT
Anticoagulation "bridging" for patients with VTE
Posted Feb 26, 2010
at 12:50 PM, EDT
by Samuel Goldhaber
Anticoagulation bridging—for a variety of reasons, from cataract surgery to teeth cleaning—is a serious and potentially risky undertaking that can provoke a number of communication issues, including errors in dosage. With little data to support the success of bridging, how can we be sure that the benefits—reducing the frequency of thrombotic events—outweigh the risk of hemorrhagic complications? When should we bridge for this type of patient?
See:
McBane RD, Wysokinski WE, Daniels PR, et al. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 2010; 30:442-448. Abstract.
Previous posts
Should we prescribe novel anticoagulants or warfarin as first line agents for stroke prevention in AF?
4 Comments |
Posted May 06, 2012
at 01:25 PM, EDT by Samuel
at 01:25 PM, EDT by Samuel
Recent PE thrombolysis trials: MAPPET, MOPETT, and MUPPET, with Dr Stavros Konstantinides
No comments |
Posted Apr 27, 2012
at 11:55 AM, EDT by Samuel
at 11:55 AM, EDT by Samuel
The US Postal Service promotes heart health
No comments |
Posted Apr 20, 2012
at 01:50 PM, EDT by Samuel
at 01:50 PM, EDT by Samuel
Thrombolysis in acute pulmonary embolism: An update with Dr Stavros Konstantinides
No comments |
Posted Apr 04, 2012
at 03:08 PM, EDT by Samuel
at 03:08 PM, EDT by Samuel
Einstein PE: Rivaroxaban shines as viable monotherapy for pulmonary embolism
1 Comments |
Posted Mar 26, 2012
at 10:25 AM, EDT by Samuel
at 10:25 AM, EDT by Samuel
Also from theheart.org
Blogs I read
Who's Talking
Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA














Comments
During that critical period when a patient is without warfarin, why not encourage the patient to be on a very low fat diet with plenty of blood thinning vegetables and fruits such as onions, garlic, ginger, celery,cucumber, papaya, pineapple, and berries are excellent for this purpose.
In addition, it is advisable to daily eat a half cup of high K1, dark green leafy vegetables to help regulate blood viscosity plus a 1 oz slice of imported cheese daily such as Gouda, Edam or Emmantaler which will supply K2 that will help to keep blood vessels supple.
I was wondering what you do with patients with mechanical mitral valves who need to stop for procedures: including those with concommitant afib.
Do you bridge? If so with Lovenox? or with Heparin?
Dear Dr. Gornitsky:
Your strategy to avoid "bridging" is an important patient safety feature. We have encouraged dentists and oral surgeons to avoid "bridging" whenever possible. Over time, I've noticed a trend toward more intensive local measures in the dental community rather than resorting to bridging with low molecular weight heparin. Has the overall dental/ oral surgical community changed its way of thinking over the past decade?--SZG
In defense of bridging...sort of. MJ Wahl, way back in '98 reviewed 493 "valve" patients who had their anticoagulation interrupted for dental procedures. Five had symptomatic TE events 4 of which were fatal (see Wahl MJ, Arcxh Inern Med. 1998:1610-1616.). Does that mean we should bridge these patients - perhaps so if we really needed to interrupt their anticoagulation. But as discussed in several postings on ClotCare.org; interruption of anticoagulation for dental procedures is unnecessary. If bleeding risk is substantial, the pre- and post-procedure of use of injectable Amicar as an oral rinse (also discussed on ClotCare) can prevent excessive bleeding. Alternatively, I will always remember my patient who lost his leg because warfarin was stopped without bridging for a colonoscopy and the little old Polish lady with atrial fibrillation whose wonderful accent I will never hear again because of the disabeling stroke that resulted from no bridging for an abdominal surgery procedure. I believe that we should carefully scrutinize the thromboembolic risk status of the patients in any study that concludes that bridging is not warranted. My understanding of the ongoing Bridge study is that the inclusion criteria will limit the patients to moderate risk patients. If the results indicate that bridging is not indicated in these patients, then the next step will be to repeat the study in higher risk patients; but we should not extrapolate finds in moderate risk patients to our higher risk patients.